Intellia Therapeutics, Inc. (NTLA)
| Market Cap | 5.29B |
| Revenue (ttm) | 62.34M |
| Net Income (ttm) | -120.32M |
| Shares Out | 58.75M |
| EPS (ttm) | -2.27 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $81.89 |
| Previous Close | $83.30 |
| Change ($) | -1.41 |
| Change (%) | -1.69% |
| Day's Open | 83.87 |
| Day's Range | 81.59 - 92.00 |
| Day's Volume | 2,622,548 |
| 52-Week Range | 9.44 - 92.00 |
Between these seven genetic editing pioneers, you have the widest exposure to the biggest scientific breakthrough of the century. The post 7 CRISPR Stocks for the Future of Medicine appeared f...
Gene editing has emerged as a promising biotech theme. The technology is used to insert, edit, or delete a gene from an organism's genome, helping to replace the defective genes responsible fo...
A leading portfolio manager recently told Bloomberg Television that gene-editing companies may turn out to be better investment opportunities than Tesla Inc. (NASDAQ:TSLA).
We all know about the red-hot sectors like electric vehicles, SPAC IPOs, and cloud based software, but the real investors know that the next industry to truly take off is in biotech, specifica...
Shares of Intellia were up as the update on its gene-editing drugs excited investors. The news also pushed up stocks of companies making gene-editing drugs, FATE, CRSP, EDIT, using CRISPR tech...
Investors are looking forward to what could be a great year for the biotechnology company.
Here we discuss three booming technological developments in the biotech sector, which can capture investor attention in 2021
CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 te...
Here we discuss five biotech stocks - EDIT, VRTX, NTLA, CBAY, MRNS - that could prove to be great investments in the long run.
The gene-editing stocks are being pulled down by a broader biotech sell-off.
Some biotech stocks have risen more than 200% this year. Here we discuss five such stocks.
Intellia is overshadowed a bit by its cousins Editas & CRISPR Therapeutics, however Intellia has a rich pipeline that looks to be focused on a few opportunities outside of its competition. The...
Crispr Therapeutics, Editas Medicine and Intellia Therapeutics were ablaze Monday as all three genetics stocks touched highs. Uniqure stock fell on a clinical hold for its gene therapy test.
Demonstrates modularity of Intellia's in vivo liver insertion technology to durably restore protein, compared to traditional gene therapy
In the Century of Biology, it pays to own the future of curing disease at the root.
CAMBRIDGE, Mass., Dec. 05, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), is presenting new preclinical data in support of NTLA-5001, the company's wholly owned Wilms' Tum...
CAMBRIDGE, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 te...
Intellia (NTLA) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 te...
Funding from the Bill & Melinda Gates Foundation to develop safe, scalable and accessible non-viral treatments for sickle cell patients
NTLA-2001: First single-course therapy that potentially halts and reverses ATTR progression
Intellia Therapeutics, Inc.'s (NTLA) CEO John Leonard on Q3 2020 Results - Earnings Call Transcript
CAMBRIDGE, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 te...
CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 te...
NTLA-2001: First single-course therapy that potentially halts and reverses ATTR
CAMBRIDGE, Mass., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Today, Jennifer Doudna, Ph.D., one of Intellia Therapeutics, Inc.’s scientific co-founders, was awarded the 2020 Nobel Prize in Chemistry fo...
CAMBRIDGE, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 te...
In Vivo g ene k nockout and i nsertion data to be presented at O TS Annual Meeting highlight modularity of Intellia’s platform and potential for variety of single-course therapies , ...
CAMBRIDGE, Mass., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9...
Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a preclinical-stage genome editing company focusing on developing novel therapeutics using the genome-editing process known as CRISPR/Cas9.
Gene editing will dramatically transform medicine and life, so should you just buy-and-hold the stocks?
CAMBRIDGE, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9...
Intellia Therapeutics (NTLA) CEO John Leonard on Q2 2020 Results - Earnings Call Transcript
Intellia Therapeutics (NTLA) CEO Ernest Garcia on Q2 2020 Results - Earnings Call Transcript
Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 11.59% and 72.13%, respectively, for the quarter ended June 2020.
CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 ...
CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 ...
Intellia Therapeutics, Inc. (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
CAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 ...
Which of these companies that are developing cutting-edge gene-editing technologies is the better buy for investors?
CAMBRIDGE, Mass., June 05, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 ...
Intellia Therapeutics (NTLA) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
CAMBRIDGE, Mass., June 02, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 ...
CAMBRIDGE, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 ...
An existing partner is doubling down on the gene editing platform.
Shares of Regeneron Pharmaceuticals Inc. REGN, +5.98% were down 0.5% in premarket trading on Monday after the company said it had expanded a collaboration with Intellia Therapeutics Inc.
Intellia Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. The post Intellia Therapeutics Sees Relative Strength Rating Rise To 92 Amid Ca...
CAMBRIDGE, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 t...
About NTLA
Intellia Therapeutics, a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company develops in vivo programs focusing on liver diseases, including transthyretin amyloidosis and hereditary angioedema, as well as other research programs comprising primary hyperoxaluria Type 1, alpha-1 antitrypsin deficiency, and Hemophilia B. Its ex vivo pipeline includes proprietary programs focused... [Read more...]
| Industry Biotechnology | IPO Date May 6, 2016 |
| CEO John Leonard | Employees 270 |
| Stock Exchange NASDAQ | Ticker Symbol NTLA |
Financial Performance
In 2019, NTLA's revenue was $43.10 million, an increase of 41.63% compared to the previous year's $30.43 million. Losses were -$99.53 million, 16.6% more than in 2018.
Analyst Forecasts
The average 12-month stock price forecast for NTLA is 66.88, which is a decrease of -18.33% from the latest price.